{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:24:10Z","timestamp":1789687450112,"version":"4.0.1"},"reference-count":175,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Soft tissue sarcomas (STSs) are rare and heterogeneous mesenchymal malignancies characterized by diverse molecular profiles and immune landscapes. Although immunotherapy has revolutionized the treatment of specific solid tumors, its efficacy in STSs remains limited and variable across histotypes. This review explores the panorama of biomarkers of immunotherapy sensitiveness in STSs, with particular emphasis on tumor-intrinsic features and on tumor microenvironment (TME) signatures. Current evidence highlights low tumor mutational burden, rare microsatellite instability, heterogeneous antigen expression, and epigenetic suppression of antigen presentation as hallmarks of the immune resistance that is characteristic of many STSs. However, growing evidence underlines TME composition as a major determinant of response to different types of immunotherapy. Indeed, the presence of B-cell-rich tertiary lymphoid structures and certain traits of adaptive immune responses are provenly associated with enhanced sensitivity to immunotherapy and enhanced outcomes. We further discuss emerging strategies aimed at enhancing STS immunogenicity, either by increasing intrinsic tumor immunogenicity or remodeling TME composition and functional profile. Collectively, the available data support a paradigm shift from a sarcoma cell-centered approach toward a multi-compartment TME-including strategy, providing a framework for the development of more effective and personalized immunotherapeutic strategies in STS.<\/jats:p>","DOI":"10.3390\/cells15141297","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:14:27Z","timestamp":1784621667000},"page":"1297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy in Soft Tissue Sarcomas\u2014An Ongoing Quest"],"prefix":"10.3390","volume":"15","author":[{"given":"Silvana","family":"Cobe\u00f1a","sequence":"first","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Oncologia M\u00e9dica, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-7341","authenticated-orcid":false,"given":"Miguel","family":"Esperan\u00e7a-Martins","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Oncologia M\u00e9dica, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal"},{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Oncology Translational Laboratory, Gulbenkian Institute for Molecular Medicine CARE, 1649-028 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Syder Queiroz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Santa Maria, 1649-035 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia","family":"Melo-Alvim","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Oncologia M\u00e9dica, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal"},{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Santa Maria, 1649-035 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-7318","authenticated-orcid":false,"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universit\u00e1ria de Oncologia M\u00e9dica, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal"},{"name":"Medical Oncology Department, Unidade Local de Sa\u00fade de Santa Maria, 1649-035 Lisboa, Portugal"},{"name":"Oncology Translational Laboratory, Gulbenkian Institute for Molecular Medicine CARE, 1649-028 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103203","DOI":"10.1016\/j.eclinm.2025.103203","article-title":"Genetic Predisposition in Sarcomas: Clinical Implications and Management","volume":"83","author":"Connolly","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lopes-Br\u00e1s, R., Lopez-Presa, D., Esperan\u00e7a-Martins, M., Melo-Alvim, C., Gallego, L., Costa, L., and Fernandes, I. (2022). Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214227"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e35772","DOI":"10.1002\/cncr.35772","article-title":"Clinician\u2019s Primer for Soft Tissue Sarcomas: Nuances of Histologic Subtypes","volume":"131","author":"Wisdom","year":"2025","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-Tissue Sarcomas in Adults","volume":"353","author":"Clark","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S1470-2045(17)30099-2","article-title":"Soft Tissue Sarcomas in Adolescents and Young Adults: A Comparison with Their Paediatric and Adult Counterparts","volume":"18","author":"Orbach","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Esperan\u00e7a-Martins, M., Vasques, H., Ravasqueira, M.S., Lemos, M.M., Fonseca, F., Coutinho, D., L\u00f3pez, J.A., Huang, R.S.P., Dias, S., and Gallego-Paez, L. (2025). Transcriptomic-Based Classification Identifies Prognostic Subtypes and Therapeutic Strategies in Soft Tissue Sarcomas. Cancers, 17.","DOI":"10.3390\/cancers17172861"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(22)00638-6","article-title":"Hypofractionated, 3-Week, Preoperative Radiotherapy for Patients with Soft Tissue Sarcomas (HYPORT-STS): A Single-Centre, Open-Label, Single-Arm, Phase 2 Trial","volume":"23","author":"Guadagnolo","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2017.74.7527","article-title":"Perioperative Management of Extremity Soft Tissue Sarcomas","volume":"36","author":"Haas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARC028): A Multicentre, Two-Cohort, Single-Arm, Open-Label, Phase 2 Trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1245\/s10434-025-18223-7","article-title":"ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk","volume":"32","author":"Callegaro","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus Tremelimumab in Advanced or Metastatic Soft Tissue and Bone Sarcomas: A Single-Centre Phase 2 Trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C-SARC032): An Open-Label, Randomised Clinical Trial","volume":"404","author":"Mowery","year":"2024","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological Response in Children and Adults with Large Unresected Intermediate-Grade or High-Grade Soft Tissue Sarcoma Receiving Preoperative Chemoradiotherapy with or without Pazopanib (ARST1321): A Multicentre, Randomised, Open-Label, Phase 2 Trial","volume":"21","author":"Weiss","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas","volume":"171","author":"Abeshouse","year":"2017","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.humpath.2020.04.007","article-title":"Tumor Mutation Burden and Checkpoint Immunotherapy Markers in Primary and Metastatic Synovial Sarcoma","volume":"100","author":"He","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical Sequencing of Soft Tissue and Bone Sarcomas Delineates Diverse Genomic Landscapes and Potential Therapeutic Targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.14377","article-title":"Mismatch Repair Deficiency Is Rare in Bone and Soft Tissue Tumors","volume":"79","author":"Lam","year":"2021","journal-title":"Histopathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1002\/cncr.34333","article-title":"Prognostic Attributes of Immune Signatures in Soft Tissue Sarcomas Show Differential Dependencies on Tumor Mutational Burden","volume":"128","author":"Raj","year":"2022","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1389366","DOI":"10.1080\/2162402X.2017.1389366","article-title":"PD-L1 and PD-1 and Characterization of Tumor-Infiltrating Lymphocytes in High Grade Sarcomas of Soft Tissue\u2014Prognostic Implications and Rationale for Immunotherapy","volume":"7","author":"Boxberg","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41379-019-0312-y","article-title":"Expression of Lymphocyte Immunoregulatory Biomarkers in Bone and Soft-Tissue Sarcomas","volume":"32","author":"Dancsok","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.4081\/ejh.2021.3203","article-title":"Characterization of PD-1\/PD-L1 Immune Checkpoint Expression in Soft Tissue Sarcomas","volume":"65","author":"Hashimoto","year":"2021","journal-title":"Eur. J. Histochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-018-1658-5","article-title":"Status of Programmed Death-Ligand 1 Expression in Sarcomas","volume":"16","author":"Park","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1737385","DOI":"10.1080\/2162402X.2020.1737385","article-title":"Osteosarcoma and Soft-Tissue Sarcomas with an Immune Infiltrate Express PD-L1: Relation to Clinical Outcome and Th1 Pathway Activation","volume":"9","author":"Wunder","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","article-title":"Clinical Genomic Profiling in the Management of Patients with Soft Tissue and Bone Sarcoma","volume":"13","author":"Gounder","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell Infiltration and Clonality Correlate with Programmed Cell Death Protein 1 and Programmed Death-ligand 1 Expression in Patients with Soft Tissue Sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vargas, A.C., Maclean, F.M., Sioson, L., Tran, D., Bonar, F., Mahar, A., Cheah, A.L., Russell, P., Grimison, P., and Richardson, L. (2020). Prevalence of PD-L1 Expression in Matched Recurrent and\/or Metastatic Sarcoma Samples and in a Range of Selected Sarcomas Subtypes. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0222551"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 Targeting in Advanced Soft-Tissue Sarcomas: A Pooled Analysis of Phase II Trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.6004\/jnccn.2022.7027","article-title":"The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook","volume":"20","author":"Banks","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Seong, G., and D\u2019Angelo, S.P. (2023). New Therapeutics for Soft Tissue Sarcomas: Overview of Current Immunotherapy and Future Directions of Soft Tissue Sarcomas. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1150765"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102115","DOI":"10.1016\/j.ctrv.2020.102115","article-title":"Sarcomas: Immune Biomarker Expression and Checkpoint Inhibitor Trials","volume":"91","author":"Zhu","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Roulleaux Dugage, M., Nassif, E.F., Italiano, A., and Bahleda, R. (2021). Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.775761"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tazzari, M., Bergamaschi, L., De Vita, A., Collini, P., Barisella, M., Bertolotti, A., Ibrahim, T., Pasquali, S., Castelli, C., and Vallacchi, V. (2021). Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147518"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.14348\/molcells.2023.0079","article-title":"Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities","volume":"46","author":"Jeong","year":"2023","journal-title":"Mol. Cells"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"He, Y., and Wu, H. (2025). Epigenetic Control of Antigen Presentation Failure in Osteosarcoma: From Single-Cell Chromatin Maps to Therapeutic Strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1728091"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The Epigenomics of Sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mosca, L., De Angelis, A., Ronchi, A., De Chiara, A., Fazioli, F., Ruosi, C., Altucci, L., Conte, M., and De Nigris, F. (2022). Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers, 14, Erratum in Cancers\u00a02026, 18, 276. https:\/\/doi.org\/10.3390\/cancers18020276.","DOI":"10.3390\/cancers18020276"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00262-021-02928-1","article-title":"Human Leukocyte Antigen I Is Significantly Downregulated in Patients with Myxoid Liposarcomas","volume":"70","author":"Oike","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-18-3704","article-title":"Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors","volume":"79","author":"Wojcik","year":"2019","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Chen, Y., Papakonstantinou, A., Tsagkozis, P., Linder-Stragliotto, C., and Haglund, F. (2022). Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas. Biomolecules, 12.","DOI":"10.3390\/biom12020292"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hale, R., Sandakly, S., Shipley, J., and Walters, Z. (2019). Epigenetic Targets in Synovial Sarcoma: A Mini-Review. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01078"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41467-025-67841-y","article-title":"Synovial Sarcoma Reprograms Transcription by GBAF Activation of Polycomb Targets and Loss of CBAF Enhancers","volume":"17","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.semdp.2020.05.005","article-title":"SWI\/SNF Complex-Deficient Soft Tissue Neoplasms: An Update","volume":"38","author":"Schaefer","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E437","DOI":"10.1002\/ijc.26478","article-title":"CIITA Is Silenced by Epigenetic Mechanisms That Prevent the Recruitment of Transactivating Factors in Rhabdomyosarcoma Cells","volume":"131","author":"Londhe","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","article-title":"NLRC5\/CITA: A Key Player in Cancer Immune Surveillance","volume":"3","author":"Yoshihama","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Albertsmeier, M., Altendorf-Hofmann, A., Lindner, L.H., Issels, R.D., Kampmann, E., D\u00fcrr, H.-R., Schubert-Fritschle, G., Angele, M.K., Kirchner, T., and Jungbluth, A.A. (2020). Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma. Cancers, 12.","DOI":"10.3390\/cancers12123612"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e70750","DOI":"10.1002\/cam4.70750","article-title":"Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China","volume":"14","author":"Chen","year":"2025","journal-title":"Cancer Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/CJI.0000000000000541","article-title":"Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics","volume":"48","author":"Vanacker","year":"2025","journal-title":"J. Immunother."},{"key":"ref_49","first-page":"3937","article-title":"Immunohistochemical Expression and Clinicopathological Assessment of the Cancer Testis Antigens NY-ESO-1 and MAGE-A4 in High-grade Soft-tissue Sarcoma","volume":"17","author":"Kakimoto","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1158\/1078-0432.CCR-19-3335","article-title":"Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas","volume":"26","author":"Moura","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Recine, F., Vanni, S., Bongiovanni, A., Fausti, V., Mercatali, L., Miserocchi, G., Liverani, C., Pieri, F., Casadei, R., and Cavaliere, D. (2024). Clinical and Translational Implications of Immunotherapy in Sarcomas. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1378398"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n, V., Villamayor, M.L., Pozas, J., Chamorro, J., Rosero, D.I., San Rom\u00e1n, M., Guerrero, P., P\u00e9rez De Aguado, P., Calvo, J.C., and Garc\u00eda De Quevedo, C. (2023). Current Landscape of Immunotherapy for Advanced Sarcoma. Cancers, 15.","DOI":"10.3389\/fimmu.2024.1352805"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-025-02533-1","article-title":"Cancer-Associated Fibroblasts in the Tumor Microenvironment: Heterogeneity, Crosstalk Mechanisms, and Therapeutic Implications","volume":"25","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11912-026-01761-y","article-title":"Revisiting the Immune Frontier in Soft Tissue Sarcomas","volume":"28","author":"Bilani","year":"2026","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B Cells Are Associated with Survival and Immunotherapy Response in Sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00262-025-04123-y","article-title":"Divergent Therapeutic and Prognostic Impacts of Immunogenic Features in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma","volume":"74","author":"Meijer","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-24-3485","article-title":"Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-24-2503","article-title":"Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma","volume":"31","author":"Lagos","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1172\/JCI139080","article-title":"Multiomic Analysis and Immunoprofiling Reveal Distinct Subtypes of Human Angiosarcoma","volume":"130","author":"Chan","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-25-3419","article-title":"Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in Sarcoma","volume":"32","author":"Rosenbaum","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Espejo Freire, A., Elliott, A., Rosenberg, A., Costa, P., Barreto-Coelho, P., Jonczak, E., D\u2019Amato, G., Subhawong, T., Arshad, J., and Diaz-Perez, J. (2021). Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. Cancers, 13.","DOI":"10.20944\/preprints202107.0068.v1"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Minopoli, M., Sarno, S., Cannella, L., Tafuto, S., Scognamiglio, G., Gallo, M., Fazioli, F., Azzaro, R., Apice, G., and De Angelis, B. (2021). Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells. Cancers, 13.","DOI":"10.3390\/cancers13133298"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sousa, L.M., Almeida, J.S., Fortes-Andrade, T., Santos-Rosa, M., Freitas-Tavares, P., Casanova, J.M., and Rodrigues-Santos, P. (2021). Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13153885"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","article-title":"The Immunosuppressive Niche of Soft-Tissue Sarcomas Is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","article-title":"Emerging Targeted and Immune-Based Therapies in Sarcoma","volume":"36","author":"Pollack","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jjco\/hyab005","article-title":"Immunotherapy for Sarcomas","volume":"51","author":"Nakata","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","article-title":"Sarcoma Microenvironment Cell States and Ecosystems Are Associated with Prognosis and Predict Response to Immunotherapy","volume":"5","author":"Subramanian","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"106801","DOI":"10.1016\/j.biocel.2025.106801","article-title":"Deciphering the Molecular Heterogeneity of Soft Tissue Sarcoma by Integrating Multiomics and Single Cell Sequence","volume":"185","author":"Zhang","year":"2025","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1896658","DOI":"10.1080\/2162402X.2021.1896658","article-title":"Influence of Tumor-Infiltrating Immune Cells on Local Control Rate, Distant Metastasis, and Survival in Patients with Soft Tissue Sarcoma","volume":"10","author":"Smolle","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41467-023-38886-8","article-title":"Single-Cell Transcriptomics Reveals Immune Suppression and Cell States Predictive of Patient Outcomes in Rhabdomyosarcoma","volume":"14","author":"DeMartino","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, G., Jian, A., Zhang, Y., and Zhang, X. (2023). A New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032961"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1385689","DOI":"10.1080\/2162402X.2017.1385689","article-title":"Analysis of the Immune Infiltrate in Undifferentiated Pleomorphic Sarcoma of the Extremity and Trunk in Response to Radiotherapy: Rationale for Combination Neoadjuvant Immune Checkpoint Inhibition and Radiotherapy","volume":"7","author":"Keung","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e70052","DOI":"10.1002\/cncr.70052","article-title":"Clinical and Biological Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcomas: IMPRESARC, a French Retrospective Multicenter Cohort Study","volume":"131","author":"Fazel","year":"2025","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell\u2013Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41419-025-08376-4","article-title":"Th17-like Cells and Immunosuppressive Macrophages Infiltrate Tertiary Lymphoid Structures with Distinct Maturation Status in Soft-Tissue Sarcoma","volume":"16","author":"Petroni","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Trontzas, I.P., and Syrigos, K.N. (2025). Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies. Cancers, 17.","DOI":"10.3390\/cancers17162639"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of All US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., and Duhon, M. (2021). FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.683419"},{"key":"ref_80","first-page":"e88647","article-title":"Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors","volume":"17","author":"Puntambekar","year":"2025","journal-title":"Cureus"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41698-026-01451-9","article-title":"Predicting Immunotherapy Benefit in Leiomyosarcoma through Active Chromatin cfDNA Profiling","volume":"10","author":"Lopes","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ijc.35477","article-title":"Blood-based Biomarkers in Soft Tissue Sarcoma: Implications for Immune Checkpoint Inhibitor Therapy","volume":"157","author":"Mannah","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current Understanding and Management of CAR T Cell-Associated Toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-21-4239","article-title":"Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells","volume":"28","author":"Goff","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1158\/1078-0432.CCR-25-0618","article-title":"A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti\u2013CTLA-4 Antibody) and Balstilimab (Anti\u2013PD-1 Antibody) in Advanced\/Metastatic Soft Tissue Sarcomas","volume":"31","author":"Wilky","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic Modifiers as New Immunomodulatory Therapies in Solid Tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Bezu, L., Wu Chuang, A., Liu, P., Kroemer, G., and Kepp, O. (2019). Immunological Effects of Epigenetic Modifiers. Cancers, 11.","DOI":"10.3390\/cancers11121911"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic Modulation of Antitumor Immunity for Improved Cancer Immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"oyaf337","DOI":"10.1093\/oncolo\/oyaf337","article-title":"Immune Checkpoint Inhibitors Combined with Tyrosine Kinase Inhibitors for Soft-Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis","volume":"30","author":"Pernomian","year":"2025","journal-title":"Oncologist"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(25)00654-0","article-title":"Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas: A Multicentre, Single-Arm, Lead-in Phase 2 Trial","volume":"27","author":"Monga","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the Tumor Microenvironment of Cold Soft-Tissue Sarcomas with Anti-Angiogenics: A Phase 2 Trial of Regorafenib Combined with Avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus Pembrolizumab in Patients with Advanced Sarcomas Including Alveolar Soft-Part Sarcoma: A Single-Centre, Single-Arm, Phase 2 Trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/eji.202149379","article-title":"Inhibition of Tumor-associated Macrophages by Trabectedin Improves the Antitumor Adaptive Immunity in Response to anti-PD-1 Therapy","volume":"51","author":"Belgiovine","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-024-01942-y","article-title":"Impact of Metronomic Trabectedin Combined with Low-Dose Cyclophosphamide on Sarcoma Microenvironment and Correlation with Clinical Outcome: Results from the TARMIC Study","volume":"23","author":"Sun","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-16-3186","article-title":"Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors","volume":"23","author":"Ratti","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Schroeder, B.A., Zhang, Y., Smythe, K.S., Desai, P., Thomas, A., Viveiros, P., Alexiev, B.A., Obeidin, F., Chen, E.Y., and Cranmer, L.D. (2022). Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients. Cancers, 14.","DOI":"10.3390\/cancers14051290"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rodrigues-Santos, P., Almeida, J.S., Sousa, L.M., Couceiro, P., Martinho, A., Rodrigues, J., Fonseca, R., Santos-Rosa, M., Freitas-Tavares, P., and Casanova, J.M. (2025). Immune Monitoring of Trabectedin Therapy in Refractory Soft Tissue Sarcoma Patients\u2014the IMMUNYON Study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1516793"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.4161\/21645515.2014.983003","article-title":"Potential for Immunotherapy in Soft Tissue Sarcoma","volume":"10","author":"Tseng","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/sajc.sajc_215_19","article-title":"Advances in Soft-Tissue Sarcoma\u2014There Are No Mistakes, Only Lessons to Learn!","volume":"08","author":"Rastogi","year":"2019","journal-title":"South Asian J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-Cell Infiltration in the Sarcoma Microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cersosimo, F., Lonardi, S., Ulivieri, C., Martini, P., Morrione, A., Vermi, W., Giordano, A., and Giurisato, E. (2024). CSF-1R in Cancer: More than a Myeloid Cell Receptor. Cancers, 16.","DOI":"10.3390\/cancers16020282"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s00262-023-03496-2","article-title":"Blockade of Tumor-Derived Colony-Stimulating Factor 1 (CSF1) Promotes an Immune-Permissive Tumor Microenvironment","volume":"72","author":"Maldonado","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Nafia, I., Toulmonde, M., Bortolotto, D., Chaibi, A., Bodet, D., Rey, C., Velasco, V., Larmonier, C.B., Cerf, L., and Adam, J. (2020). IDO Targeting in Sarcoma: Biological and Clinical Implications. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00274"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e70066","DOI":"10.1002\/jcp.70066","article-title":"Metabolic Effects of Succinate Dehydrogenase Loss in Cancer","volume":"240","author":"Chatoff","year":"2025","journal-title":"J. Cell. Physiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/2767-9764.CRC-25-0468","article-title":"Succinate Dehydrogenase B (SDHB) Overexpression with Enzymatic Dysfunction Defines a Distinct Subtype of Undifferentiated Pleomorphic Sarcoma","volume":"5","author":"Vasques","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1126\/science.abq1053","article-title":"Manipulating Mitochondrial Electron Flow Enhances Tumor Immunogenicity","volume":"381","author":"Mangalhara","year":"2023","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2025.01.005","article-title":"Mitochondrial Succinate Feeds T Cell Exhaustion in Cancer","volume":"43","author":"Galluzzi","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-024-01614-w","article-title":"Predictive Value of Tumor Microenvironment on Pathologic Response to Neoadjuvant Chemotherapy in Patients with Undifferentiated Pleomorphic Sarcomas","volume":"17","author":"Guegan","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"103131","DOI":"10.1016\/j.ebiom.2020.103131","article-title":"High Throughput Profiling of Undifferentiated Pleomorphic Sarcomas Identifies Two Main Subgroups with Distinct Immune Profile, Clinical Outcome and Sensitivity to Targeted Therapies","volume":"62","author":"Toulmonde","year":"2020","journal-title":"eBioMedicine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-024-01946-8","article-title":"Reshaping the Tumor Microenvironment of Cold Soft-Tissue Sarcomas with Oncolytic Viral Therapy: A Phase 2 Trial of Intratumoral JX-594 Combined with Avelumab and Low-Dose Cyclophosphamide","volume":"23","author":"Toulmonde","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"86769","DOI":"10.18632\/oncotarget.21423","article-title":"Oncolytic Reovirus Inhibits Angiogenesis through Induction of CXCL10\/IP-10 and Abrogation of HIF Activity in Soft Tissue Sarcomas","volume":"8","author":"Carew","year":"2017","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e012446","DOI":"10.1136\/jitc-2025-012446","article-title":"Addition of Oncolytic Virotherapy to Clinical Isolated Limb Perfusion for Melanoma and Sarcoma Activates Antitumor Immunity","volume":"13","author":"Hayes","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective Response Rate Among Patients with Locally Advanced or Metastatic Sarcoma Treated with Talimogene Laherparepvec in Combination with Pembrolizumab: A Phase 2 Clinical Trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","article-title":"Metabolic Targeting of Cancer Associated Fibroblasts Overcomes T-Cell Exclusion and Chemoresistance in Soft-Tissue Sarcomas","volume":"15","author":"Broz","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"115628","DOI":"10.1016\/j.ejca.2025.115628","article-title":"Fighting Sarcomas at the Root: The Role of Mesenchymal Stem Cells in Sarcomagenesis","volume":"227","author":"Chantoiseau","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.5357","article-title":"Mesenchymal Stromal Cells in Cancer: A Review of Their Immunomodulatory Functions and Dual Effects on Tumor Progression","volume":"250","author":"Galland","year":"2020","journal-title":"J. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Walter, S.G., Scheidt, S., Ni\u00dfler, R., Gaisendrees, C., Zarghooni, K., and Schildberg, F.A. (2021). In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. Cancers, 13.","DOI":"10.3390\/cancers13061466"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"115622","DOI":"10.1016\/j.biopha.2023.115622","article-title":"Microenvironmental Regulation in Tumor Progression: Interactions between Cancer-Associated Fibroblasts and Immune Cells","volume":"167","author":"Gao","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Hazrati, A., Malekpour, K., Mirsanei, Z., Khosrojerdi, A., Rahmani-Kukia, N., Heidari, N., Abbasi, A., and Soudi, S. (2023). Cancer-Associated Mesenchymal Stem\/Stromal Cells: Role in Progression and Potential Targets for Therapeutic Approaches. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1280601"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sun, L., and Yao, Y. (2023). Mesenchymal Stem\/Stromal Cells- a Principal Element for Tumour Microenvironment Heterogeneity. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1274379"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-016-0740-2","article-title":"Tumor-Associated Stromal Cells as Key Contributors to the Tumor Microenvironment","volume":"18","author":"Bussard","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12943-022-01670-1","article-title":"Targeting the Tumor Stroma for Cancer Therapy","volume":"21","author":"Xu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1093\/oncolo\/oyad052","article-title":"Emerging Trends in Immunotherapy for Adult Sarcomas","volume":"28","author":"Husain","year":"2023","journal-title":"Oncologist"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jconrel.2022.12.016","article-title":"Translational Nanomedicine Potentiates Immunotherapy in Sarcoma by Normalizing the Microenvironment","volume":"353","author":"Mpekris","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in Patients with Rare and Ultra-Rare Sarcomas (AcS\u00e9 Pembrolizumab): Analysis of a Subgroup from a Non-Randomised, Open-Label, Phase 2, Basket Trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for Advanced Alveolar Soft Part Sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"116104","DOI":"10.1016\/j.ejca.2025.116104","article-title":"Clinical, Immunological, and Genomic Findings of Atezolizumab in Advanced Alveolar Soft Part Sarcoma: A Phase II Trial (ALBERT Trial\/NCCH1907)","volume":"232","author":"Kojima","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.2174\/1381612828666220921151750","article-title":"Comparative Combinatorial Implications and Theranostics of Immunotherapy Inthe Impediment of Alveolar Soft Part Sarcoma","volume":"28","author":"Yang","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1002\/cncr.31517","article-title":"Rationale and Emerging Strategies for Immune Checkpoint Blockade in Soft Tissue Sarcoma","volume":"124","author":"Wisdom","year":"2018","journal-title":"Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.semradonc.2023.12.005","article-title":"Immunotherapy and Radiotherapy Combinations for Sarcoma","volume":"34","author":"Zhang","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41417-023-00720-0","article-title":"BETA Prime: A First-in-Man Phase 1 Study of AdAPT-001, an Armed Oncolytic Adenovirus for Solid Tumors","volume":"31","author":"Conley","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e010543","DOI":"10.1136\/jitc-2024-010543","article-title":"Intratumoral Oncolytic Virus OH2 Injection in Patients with Locally Advanced or Metastatic Sarcoma: A Phase 1\/2 Trial","volume":"13","author":"Tan","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.semradonc.2024.01.001","article-title":"Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas","volume":"34","author":"Su","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","article-title":"Immune Checkpoint Inhibitors in Treatment of Soft-Tissue Sarcoma: A Systematic Review and Meta-Analysis","volume":"152","author":"Saerens","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-Label, Non-Comparative, Randomised, Phase 2 Trials","volume":"19","author":"Mahoney","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Oliva-Ramirez, J., Milewski, D., Banks, L., Bailey, K.M., Moding, E.J., Lake, J., Chen, A., Daley, J.D., Resch, E.E., and Kaplan, R.N. (2025). Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout. Cancers, 17.","DOI":"10.3390\/cancers17183068"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CCO.0000000000000843","article-title":"Immunotherapy of Sarcomas with Modified T Cells","volume":"34","author":"Mahalingam","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s11912-025-01706-x","article-title":"Adoptive T-Cell Therapy in Sarcomas","volume":"27","author":"Kucharczyk","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma (SPEARHEAD-1): An International, Open-Label, Phase 2 Trial","volume":"403","author":"Araujo","year":"2024","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Fradin, J.J., and Charlson, J.A. (2025). Review of Adoptive Cellular Therapies for the Treatment of Sarcoma. Cancers, 17.","DOI":"10.3390\/cancers17081302"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker Correlates with Response to NY-ESO-1 TCR T Cells in Patients with Synovial Sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1\u2013Reactive T-Cell Receptor: Long-Term Follow-up and Correlates with Response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO-24-01466","article-title":"Letetresgene Autoleucel in Advanced\/Metastatic Myxoid\/Round Cell Liposarcoma","volume":"43","author":"Druta","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I\/II Clinical Trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A Phase 1 Trial of NY-ESO-1-specific TCR -engineered T-cell Therapy Combined with a Lymph Node-targeting Nanoparticulate Peptide Vaccine for the Treatment of Advanced Soft Tissue Sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","article-title":"A Pilot Trial of the Combination of Transgenic NY-ESO-1\u2013Reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab","volume":"25","author":"Nowicki","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1038\/s41467-025-60816-z","article-title":"Human Cancer-Targeted Immunity via Transgenic Hematopoietic Stem Cell Progeny","volume":"16","author":"Nowicki","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","article-title":"Latest Updates on Pathogenesis Mechanisms and Management Strategies for Cytokine Release Syndrome, Neurotoxicity, and Hemophagocytic Lymphohistiocytosis Related to CAR-T Cell Therapies","volume":"104","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Tzannou, I., Vardi, A., Tsonis, I., Liga, M., Gkirkas, K., Ximeri, M., Bousiou, Z., Bouzani, M., and Sagiadinou, E. (2025). Management Strategies for CAR-T Cell Therapy-Related Toxicities: Results from a Survey in Greece. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1553966"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of Cytokine Release Syndrome and Neurotoxicity of CAR T-Cell Therapy and Associated Prevention and Management Strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/imr.13233","article-title":"Challenges and Solutions for Therapeutic TCR -based Agents","volume":"320","author":"Malviya","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR Engineered T Cell Performance as a Function of Tumor Cell Exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"OncoImmunology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the Storm: Managing Cytokine-Related Toxicities in CAR-T Cell Therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin. Immunopathol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular Toxicity and Titin Cross-Reactivity of Affinity-Enhanced T Cells in Myeloma and Melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T Cell Receptor-based Cancer Immunotherapy: Emerging Efficacy and Pathways of Resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40264-025-01538-5","article-title":"Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients","volume":"48","author":"Renninger","year":"2025","journal-title":"Drug Saf."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1245\/s10434-022-12517-w","article-title":"Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma","volume":"29","author":"Delisle","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e232654","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1054\/bjoc.2001.2180","article-title":"Uptake of IgG in Osteosarcoma Correlates Inversely with Interstitial Fluid Pressure, but Not with Interstitial Constituents","volume":"85","author":"Davies","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Donelan, W., Dominguez-Gutierrez, P.R., and Kusmartsev, S. (2022). Deregulated Hyaluronan Metabolism in the Tumor Microenvironment Drives Cancer Inflammation and Tumor-Associated Immune Suppression. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.971278"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e167826","DOI":"10.1172\/JCI167826","article-title":"Oncogene-Induced Matrix Reorganization Controls CD8+ T Cell Function in the Soft-Tissue Sarcoma Microenvironment","volume":"134","author":"Fuller","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-23-3960","article-title":"Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas","volume":"30","author":"Pankova","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Baronzio, G., Parmar, G., and Baronzio, M. (2015). Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00165"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12935-024-03520-0","article-title":"Acid Affairs in Anti-Tumour Immunity","volume":"24","author":"Cappellesso","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","article-title":"Hypoxia Promotes Tumor Immune Evasion by Suppressing MHC-I Expression and Antigen Presentation","volume":"44","author":"Estephan","year":"2025","journal-title":"EMBO J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"120057","DOI":"10.1016\/j.lfs.2021.120057","article-title":"The Impact of Hypoxia on Immune State in Cancer","volume":"286","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e3633","DOI":"10.1002\/cnm.3633","article-title":"The Modeling Study of the Effect of Morphological Behaviors of Extracellular Matrix Fibers on the Dynamic Interaction between Tumor Cells and Antitumor Immune Response","volume":"38","author":"Jia","year":"2022","journal-title":"Int. J. Numer. Methods Biomed. Eng."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imm.70094","article-title":"Barriers and Strategies to Enhance CAR -T Cell Infiltration in Solid Tumours: A Systematic Review","volume":"178","author":"Zhang","year":"2026","journal-title":"Immunology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"103003","DOI":"10.1016\/j.ctrv.2025.103003","article-title":"How to Foster New Treatment Development in Ultra-Rare Tumours? Joint EMA-EORTC Multi-Stakeholder Workshops on Ultra-Rare Sarcomas as a Model for Rare Cancers","volume":"140","author":"Stacchiotti","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical Trial Designs for Rare Diseases: Studies Developed and Discussed by the International Rare Cancers Initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdu459","article-title":"Rare Cancers Europe (RCE) Methodological Recommendations for Clinical Studies in Rare Cancers: A European Consensus Position Paper","volume":"26","author":"Casali","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:32:39Z","timestamp":1784622759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":175,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141297"],"URL":"https:\/\/doi.org\/10.3390\/cells15141297","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}